Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 2INDUSTRY 2NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Oligodendroglioma 2Central Nervous System Neoplasms 2Astrocytoma 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Spinal Cord Neoplasms 1Rhabdoid Tumor 1Optic Nerve Glioma 1Medulloblastoma 1Gliosarcoma 1Glioma, Subependymal 1Glioma 1Glioblastoma 1Familial ependymoma 1Ependymoma 1Choroid Plexus Neoplasms 1Breast Neoplasms, Male 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Cyclophosphamide 39Docetaxel 30Tamoxifen 29Paclitaxel 27Doxorubicin 26Trastuzumab 20Radiotherapy 18Epirubicin 16Letrozole 13exemestane 11Fluorouracil 11Anastrozole 11Capecitabine 10Bevacizumab 10Immunohistochemistry 9Filgrastim 9Fulvestrant 8Methotrexate 7Gene Expression Profiling 7palbociclib 6Zoledronic Acid 6Microarray Analysis 6Lapatinib 6Goserelin 6Chemotherapy, Adjuvant 6Amplified Fragment Length Polymorphism Analysis 6Vinorelbine 5Triptorelin Pamoate 5Carboplatin 5Absorptiometry, Photon 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Breast Neoplasms × lonafarnib × Clear all
NCT00068757 2012-09-12

Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Phase 1 Completed
23 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡